Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR139 | Q6DWJ6 | 3/20 | 0.37 |
| ▸ | AKT1 | P31749 | 1/20 | 0.34 |
| ▸ | AKT2 | P31751 | 1/20 | 0.34 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.31 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.31 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.31 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.31 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15767157 | 0.83 | GPR139 (0.34) | GPR139AKT1AKT2GABRA1GABRG2 | |
| SCHEMBL14572002 | 0.68 | KDM4E (0.33) | — | |
| SCHEMBL14276910 | 0.68 | KDM4E (0.40) | AKT1AKT2 | |
| SCHEMBL14685219 | 0.67 | CYP1A2 (0.42) | AKT1AKT2PDE10A | |
| SCHEMBL15077682 | 0.66 | KMT2A (0.42) | PDE10A | |
| SCHEMBL15767066 | 0.66 | SUV39H2 (0.32) | GPR139 | |
| SCHEMBL30939171 | 0.65 | AKT1 (0.36) | GPR139AKT1AKT2GABRA1GABRG2 | |
| SCHEMBL2738311 | 0.65 | ALDH1A1 (0.55) | PDE10A | |
| SCHEMBL31729104 | 0.64 | GPR139 (0.39) | GPR139AKT1AKT2 | |
| SCHEMBL7224848 | 0.63 | GABRG2 (0.43) | GPR139AKT1AKT2GABRA1GABRG2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2740730-B1 | DIBENZOOXEPIN DERIVATIVE | KYOWA HAKKO KIRIN CO LTD (JP) | 2016-11-16 | — | — | EP | disclosed |
| US-8969345-B2 | Dibenzooxepin derivative | KYOWA HAKKO KIRIN CO., LTD. (JP) | 2015-03-03 | — | — | US | disclosed |
| US-20140163008-A1 | DIBENZOOXEPIN DERIVATIVE | KYOWA HAKKO KIRIN CO., LTD. (JP) | 2014-06-12 | — | — | US | disclosed |
| EP-2740730-A1 | DIBENZOOXEPIN DERIVATIVE | Kyowa Hakko Kirin Co., Ltd. (JP) | 2014-06-11 | — | — | EP | disclosed |
| WO-2013018899-A1 | DIBENZOOXEPIN DERIVATIVE | 協和発酵キリン株式会社 (JP) | 2013-02-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140163008-A1 | DIBENZOOXEPIN DERIVATIVE | PPARA, PPARG, PPARD | GPR139 495/4885AKT1 854/4885AKT2 571/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.